Literature DB >> 34112087

Clinical features of NK/T-cell EBV-associated LPD manifested as gastrointestinal symptoms in patients with normal immunity: a case report and literature review.

Si-Zhu Wang1,2, Ying-Huan Dai3, Jie Zhang4,5, Fang-Gen Lu1,2, La-Mei Yan1,2, Shan Wu1,2.   

Abstract

BACKGROUND: Epstein-Barr virus (EBV)-associated NK/T-cell lymphoproliferative disorder (LPD) involving the gastrointestinal tract is rarely observed in individuals with normal immunity. The atypical clinical, colonoscopic manifestations often confuse clinicians, leading to misdiagnosis and delays in the treatment. CASE
PRESENTATION: Herein, we reported on a single case of a patient with gastrointestinal symptoms. Several colonoscopies showed multiple irregular ulcerations, while biopsies showed colitis with infiltration of neutrophils or lymphocytes. After 2 months follow-up, the patient was diagnosed with the extranodal NK/T-cell lymphoma, nasal type, and was treated with thalidomide. Later on, a second check was performed on his first pathological sample. Immunohistochemistry revealed EBV associated NK/T-cell LPD.
CONCLUSIONS: Multiple, multiform, and segmental gastrointestinal ulcers should be an indication for EBV infection, regardless of the presence of fever, lymphadenopathy, and hepatosplenomegaly. If EBV-associated NK/T-cell LPD is considered, serum EBV-DNA should be measured, and the tissue obtained by biopsy should be carefully analyzed for a positive expression of the EBER marker.

Entities:  

Keywords:  Diagnosis; Epstein–Barr virus; Immunocompetent; Intestine; NK/T-cell lymphoproliferative disease

Year:  2021        PMID: 34112087     DOI: 10.1186/s12876-021-01718-4

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


  1 in total

1.  Endoscopic findings of small-intestinal Epstein-Barr virus-associated T-cell lymphoproliferative disorder.

Authors:  S Sazuka; Y Takahashi; T Kawaguchi; T Sato; T Nakagawa; Y Furuya; M Saito; K Saito; T Katsuno; C Nakaseko; O Yokosuka
Journal:  Endoscopy       Date:  2012-03-06       Impact factor: 10.093

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.